WNTresearch
WNTresearch - WNT researchWNTresearchWNTresearchWNTresearch

WNT research

  • WntResearch
    • About WntResearch
    • Business concept and strategies
    • market Potential
    • Interview with the founder
    • History
    • Scientific advisors
  • Pipeline
    • Foxy-5
      • Phase 1 study
      • Phase 2 study
    • Articles
    • metastases
    • WNT signaling
    • Partners
      • Allucent
      • Biovica
      • SAGA diagnostics
      • The Sage Group
    • Box-5
    • Patents
  • Investor
    • Financial reports
    • Warrants series 2021/2023
    • Share issues
      • Rights issue 2022
    • The Share
    • presentations
    • Financial calendar
  • NEWS
    • Press Releases
    • Subscribe
  • Corporate Governance
    • Nomination committee
    • General meetings
    • Management
    • Board
    • Articles of association
  • Contact
  • English
    • Swedish

Share issues

WNTresearch   →  Share issues

Share issues

2021

Link to the Swedish Rights issue page.

2019

  • Memorandum 2019
  • Press release 28 February 2019
  • Convocation of extraordinary general meeting
  • Resolution on preferential rights issue
  • Proxy form
  • WntResearch Annual Report 2017
  • Statement from the Board of Directors according to
  • Auditor’s opinion on the Board of Directors’s statement

2018

  • Information about TO3

2017

  • Press release 27 November 2017
  • Prospectus 2017
  • Press release 31 May 2017

2016

  • Press release 9 May 2016
  • Memorandum

2014

  • Memorandum

2013

  • Memorandum

A new approach to fight tumour spread!
Foxy-5 is a unique drug candidate:
Significant medical need, first-in-class, unique mode of action, excellent pharmacokinetics, strong preclinical efficacy data, favourable safety profile

QUICK LINKS

  • Phase 2 study
  • Press Releases
  • shares

Subscribe

    

Copyright © All rights reserved.